New eye injection shows promise for Diabetes-Related vision loss

NCT ID NCT05959304

First seen Jan 04, 2026 · Last updated May 10, 2026 · Updated 27 times

Summary

This study tested the safety and effectiveness of brolucizumab eye injections in 66 adults with diabetic macular edema, a condition that causes vision loss in people with diabetes. Participants received injections over 40 weeks to see if their vision improved and to track any side effects. The goal was to gather real-world data in Indian patients to support ongoing use of this treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Novartis Investigative Site

    Ahmedabad, Gujarat, 380052, India

  • Novartis Investigative Site

    Bangalore, Karnataka, 560 010, India

  • Novartis Investigative Site

    Kochi, Kerala, 682 026, India

  • Novartis Investigative Site

    Chennai, Tamil Nadu, 600045, India

  • Novartis Investigative Site

    Kolkata, West Bengal, 700 073, India

  • Novartis Investigative Site

    Coimbatore, 641002, India

  • Novartis Investigative Site

    Kolkata, 700120, India

  • Novartis Investigative Site

    New Delhi, 110029, India

Conditions

Explore the condition pages connected to this study.